Apricus' stock rises on transdermal platform success; Echo gets patents for needle-free tech;

 @DamianFierce: Drugmakers are rethinking drug delivery methods for multiple sclerosis treatments. Report | Follow @DamianFierce

> Drug delivery firm Apricus Bio's stock has gone up nearly 30% over the last month, and that trend is likely to continue thanks to its NexACT delivery platform. News

> Echo Therapeutics ($ECTE) has secured patents for Symphony, its needle-free glucose monitor, and Prelude, the transdermal platform that makes it work. Story

> IntelGenx ($IGXT) got its OTC Markets listing upgraded, from OTCQB to OTCQX, OTC's highest tier. Release

> Fuse Science is touting positive study results for its transdermal delivery platform, eyeing partnerships in pharmaceuticals and consumer products. More

> Another firm has found a way to use chocolate as a platform to boost the efficacy of treatments. Item